Clinical trials: Lupus Erythematosus
Systemic Lupus Erythematosus
Effect of Applying Ujjayi Pranayama on Cortisol in Lupus Patients
stress vulnerability is very common in lupus patients, specifically women, hence the rates of depression , insomnia, easy fatigue perception, anxiety are high in those women.
- Trial name
- NCT05748899
- Testing
- Ujjayi pranayama
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Badr University
Systemic Lupus Erythematosus, Sjogren's Syndrome
Cell Surface Marker Expression in Autoimmune Diseases
This study is designed to explore the expression of cell-surface markers in the following seven disease areas: (a) systemic lupus erythematosus, (b) Sjogren's syndrome, (c) multiple sclerosis, (d) systemic sclerosis, (e) Crohn's…
- Conditions
- Systemic Lupus Erythematosus, Sjogren's Syndrome, Multiple Sclerosis, Systemic Sclerosis
- Trial name
- CASCADE (NCT03757065)
- Where
- 2 sites in Canada
- Volunteers
- 14 people
- Sponsor
- Alpine Immune Sciences, Inc.
Systemic Lupus Erythematosus, Fibromyalgia
Magnetic Resonance Spectroscopy, Perfusion and Diffusion Tensor Imaging in Neuropsychiatric Lupus
The purpose of this study is to find out if certain types of Magnetic Resonance (MR) scanning will help to better detect markers in the brain that are related to the neuropsychiatric symptoms of systemic lupus erythematosus…
- Conditions
- Systemic Lupus Erythematosus, Fibromyalgia, Acute Neuropsychiatric Lupus
- Trial name
- NCT00723671
- Testing
- MRI
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Mixed Connective Tissue Disease (MCTD), Systemic Lupus Erythematosus (SLE)
Characteristics and Disease Progression of Mixed Connective Tissue Disease and Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD) are long-term autoimmune diseases in which the immune system attacks parts of the body.
- Trial name
- NCT00582881
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- University of Miami
Systemic Lupus Erythematosus
A Phase 2 Clinical Study of MIL62 in Systemic Lupus Erythematosus
This study will evaluate the efficacy, safety, pharmacokinetics(PK), pharmacodynamics(PD) and ADA of MIL62 compared with placebo in participants with systemic lupus erythematosus.
- Trial name
- NCT05796206
- Testing
- MIL62
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Beijing Mabworks Biotech Co., Ltd.
Lupus Erythematosus, Systemic
CD19-Directed CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease in which the immune system mistakenly attacks the body's own tissues and organs.
- Trial name
- CLEVER-SLE (NCT07659704)
- Testing
- Autologous CD19-Directed CAR-T Cells Manufactured at Ribeirão Preto Blood Center
- Where
- 2 sites in Brazil
- Volunteers
- 16 people
- Sponsor
- University of Sao Paulo
Systemic Lupus Erythematosus
UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Systemic Lupus Erythematosus
This is an open label, single-site, dose-escalation study in up to 18 participants with relapsed or refractory Systemic lupus erythematosus.
- Trial name
- NCT06920433
- Testing
- UCAR T-cell group
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Zhejiang University
Cutaneous Lupus Erythematosus
IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus
The purpose of this research study is to show that non-steroidal treatment with intravenous immunoglobulin (IVIg) can replace current systemic immunosuppressive therapy in cutaneous lupus erythematosis (CLE) patients.
- Trial name
- NCT01841619
- Testing
- IVIg
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- University of California, Irvine
Systemic Lupus Erthematosus (SLE), Lupus Nephritis (LN)
A Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune Diseases
This is an investigator-initiated, open-label, single-arm, dose-escalation and dose-expansion study to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of MTM-H-001 in adult participants with B-cell-related…
- Conditions
- Systemic Lupus Erthematosus (SLE), Lupus Nephritis (LN), Multiple Sclerosis, Myasthenia Gravis (MG)
- Trial name
- ArchAid-002 (NCT07593911)
- Testing
- MTM-H-001 Injection
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Beijing GoBroad Hospital
Systemic Lupus Erythematosus, Pregnancy Complications
The Lupus prEGnAnCY Cohort: An International Prospective Cohort of Lupus Pregnancies
The goal is to evaluate adverse pregnancy outcomes (APO), their predictors and potential preventive therapies, such as aspirin (ASA). The investigator aims to improve the outcomes for women with SLE and offsprings.
- Trial name
- LEGACY (NCT03746028)
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Systemic Lupus Erythematosus (SLE)
An Exploratory Clinical Study of Anti-CD19 CAR NK Cells in the Treatment of Systemic Lupus Erythematosus
A single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-cluster of differentiation antigen 19 (CD19) chimeric antigen receptor (CAR) natural killer (NK) cells (KN5501) in patients with…
- Trial name
- NCT06010472
- Testing
- anti-CD19 CAR NK cells (KN5501)
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Changhai Hospital
Systemic Lupus Erythematosus
A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02
This is a continuation study to evaluate the long-term safety and efficacy of LymphoStat-B™ in subjects with SLE disease, that completed study LBSL02 and benefitted from treatment.
- Trial name
- NCT00583362
- Testing
- Belimumab
- Where
- 57 sites in United States, Canada
- Volunteers
- 298 people
- Sponsor
- Human Genome Sciences Inc., a GSK Company
Lupus Nephritis
Serological and Urinary Biomarkers in Latin American Patients With Systemic Lupus Erythematosus: GLADEL 2.0 Cohort
Lupus nephritis (LN) is one of the main manifestationsin SLE patients, having an important impact on morbidity and mortality. Renal biopsy is the "gold standard" for the diagnosis of LN, however, it is an invasive technique, not…
- Trial name
- NCT04534647
- Testing
- different serum and urine biomarkers
- Where
- Argentina
- Volunteers
- 100 people
- Sponsor
- Liga Panamericana de Asociaciones de Reumatologia (PANLAR)
Healthy, Systemic Lupus Erythematosus
A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
The purpose of this study is to investigate the safety and tolerability of LY4298445 in healthy participants and in participants with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA).
- Conditions
- Healthy, Systemic Lupus Erythematosus, Rheumatoid Arthritis
- Trial name
- NCT07276958
- Testing
- LY4298445
- Where
- 10 sites in Australia, China and 1 more
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Systemic Lupus Erythematosus
Randomized Study of Oral Contraceptives or Hormone Replacement Therapy in Women With Systemic Lupus Erythematosus
OBJECTIVES: I. Determine the effect of oral contraceptives containing low-dose synthetic estrogens and progestins on disease activity in premenopausal women with inactive, stable, or moderate systemic lupus erythematosus (SLE).
- Trial name
- NCT00006133
- Testing
- estradiol, ethinyl estradiol, medroxyprogesterone
- Where
- 17 sites in United States
- Volunteers
- 970 people
- Sponsor
- National Center for Research Resources (NCRR)
CAR-T
Phase I Clinical Study of GC012F Injection in Treatment of Refractory Systemic Lupus Erythematosus
This is a phase I, single arm, non-randomized, open label, treatment study trial to determine the recommended phase II dose of GC012F injection (CD19-BCMA CAR-T cells) in patients with refractory systemic lupus erythematosus.
- Trial name
- NCT05846347
- Testing
- GC012F injection
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Zhejiang University
Subacute Cutaneous Lupus Erythematosus
Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus
This study will assess the safety and efficacy of KRP203 in clinically active subacute cutaneous lupus erythematosus patients, who have demonstrated inadequate response to standard treatment, such as antimalarials.
- Trial name
- NCT01294774
- Testing
- KRP203 - 1.2mg
- Where
- 8 sites in Germany, Greece and 1 more
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Lupus Erythematosus, Lupus Nephritis
An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus
The study is intended to assess safety, efficacy and cellular kinetics of YTB323 treatment in participants with severe refractory systemic lupus erythematosus.
- Trial name
- NCT05798117
- Testing
- YTB323
- Where
- 10 sites in Australia, France and 3 more
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Lupus Erythematosus
The Role of Some Hematological Parameters in Juvenile Systemic Lupue Erythematosus
Juvenile systemic lupus erythematosus is an autoimmune disorder with multisystem involvement, leading to inflammatory damage to the joints, kidney, central nervous system, and hematopoietic system.
- Trial name
- NCT06227559
- Volunteers
- 60 people
- Sponsor
- Assiut University
Systemic Lupus Erythematosus (SLE)
An Open-label Study of GB261 in Refractory Seropositive Systemic Lupus Erythematosus
The purpose of the study is to evaluate the safety and efficacy of CD20xCD3 T-cell engager (GB261) in patients with refractory seropositive systemic lupus erythematosus.
- Trial name
- NCT06945068
- Testing
- GB261
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology